NewAmsterdam Pharma (NAMS) Institutional Ownership → Warning: this could blow your mind (From DTI) (Ad) Free NAMS Stock Alerts $23.65 +0.95 (+4.19%) (As of 03/28/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for NewAmsterdam Pharma (NASDAQ:NAMS)CurrentInstitutional OwnershipPercentage89.89%Number ofInstitutional Buyers(last 12 months)18TotalInstitutional Inflows(last 12 months)$268.31 MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$245,269.23 Get NAMS Insider Trade Alerts Want to know when executives and insiders are buying or selling NewAmsterdam Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NAMS Institutional Buying and Selling by Quarter Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… NewAmsterdam Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails3/7/2024Fcpm Iii Services B.V.11,831,461$132.16M39.2%N/A14.373% 3/1/2024Goldman Sachs Group Inc.1,384,321$15.46M0.0%N/A1.682% 2/15/2024Opaleye Management Inc.265,388$2.96M0.8%N/A0.325% 2/15/2024Parkman Healthcare Partners LLC300,750$3.36M0.5%+20.8%0.369% 2/15/2024Citadel Advisors LLC21,046$0.24M0.0%-33.0%0.026% 2/14/2024Royal Bank of Canada10,875$0.12M0.0%+987.5%0.013% Get the Latest News and Ratings for NAMS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. 2/13/2024Goldman Sachs Group Inc.1,384,321$15.46M0.0%N/A1.697% 2/1/2024 Wolverine Asset Management LLC8,694$97K0.0%+197.2%0.011% 11/15/2023Affinity Asset Advisors LLC125,000$1.16M0.3%+25.0%0.153% 11/14/2023Schonfeld Strategic Advisors LLC64,700$0.60M0.0%+12.9%0.079% 11/13/2023 Wolverine Asset Management LLC2,925$27K0.0%N/A0.004% 8/21/2023Affinity Asset Advisors LLC100,000$1.19M0.4%N/A0.123% 8/15/2023RA Capital Management L.P.9,000,000$107.01M2.0%+125.0%11.035% 8/15/2023Bain Capital Life Sciences Investors LLC10,473,913$124.54M12.8%+26.2%12.842% 8/14/2023Schonfeld Strategic Advisors LLC57,300$0.68M0.0%+90.4%0.070% 8/14/2023Marshall Wace LLP25,361$0.30M0.0%N/A0.031% 8/11/2023Geode Capital Management LLC25,768$0.31M0.0%+38.8%0.032% 8/11/2023JPMorgan Chase & Co.11,463$0.14M0.0%-48.8%0.014% 8/10/2023Monashee Investment Management LLC95,000$1.13M0.3%N/A0.116% 8/4/2023Maven Securities LTD25,000$0.30M0.0%N/A0.031% 7/19/2023 Medicxi Ventures Management Jersey Ltd2,869,565$34.12M9.6%+43.5%3.518% 7/14/2023 Venture Visionary Partners LLC10,000$0.12M0.0%N/A0.012% 5/18/2023JPMorgan Chase & Co.22,367$0.30M0.0%+1,929.7%0.126% 5/16/2023Geode Capital Management LLC18,559$0.25M0.0%N/A0.105% 5/15/2023Schonfeld Strategic Advisors LLC30,100$0.40M0.0%N/A0.170% 5/9/2023GMT Capital Corp1,083,800$14.37M0.6%+8.4%6.106% 5/8/2023 Wolverine Asset Management LLC4,819$64K0.0%N/A0.027% 2/14/2023RA Capital Management L.P.4,000,000$43.60M0.9%N/A22.535% 2/14/2023Alyeska Investment Group L.P.200,000$1.89M0.0%N/A1.127% 2/3/2023Frazier Life Sciences Management L.P.9,341,551$101.82M6.3%N/A52.628% 2/3/2023GMT Capital Corp1,000,000$10.90M0.5%N/A5.634% 1/31/2023 Medicxi Ventures Management Jersey Ltd2,000,000$21.80M9.2%N/A11.268% (Data available from 1/1/2016 forward) NAMS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NAMS shares? During the previous two years, 21 institutional investors and hedge funds held shares of NewAmsterdam Pharma. The most heavily invested institutionals were Fcpm Iii Services B.V. ($132.16M), Bain Capital Life Sciences Investors LLC ($124.54M), RA Capital Management L.P. ($107.01M), Frazier Life Sciences Management L.P. ($101.82M), Medicxi Ventures Management Jersey Ltd ($34.12M), Goldman Sachs Group Inc. ($15.46M), and GMT Capital Corp ($14.37M).Learn more on NAMS's institutional investors. What percentage of NewAmsterdam Pharma stock is owned by institutional investors? 89.89% of NewAmsterdam Pharma stock is owned by institutional investors. Learn more on NAMS's institutional investor holdings. Which institutional investors have been buying NewAmsterdam Pharma stock? Of the 20 institutional investors that purchased NewAmsterdam Pharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Fcpm Iii Services B.V. ($11.83M), Frazier Life Sciences Management L.P. ($9.34M), RA Capital Management L.P. ($9M), Medicxi Ventures Management Jersey Ltd ($2.87M), Goldman Sachs Group Inc. ($2.77M), Bain Capital Life Sciences Investors LLC ($2.17M), and GMT Capital Corp ($1.08M). How much institutional buying is happening at NewAmsterdam Pharma? Institutional investors have bought a total of 40,001,528 shares in the last 24 months. This purchase volume represents approximately $448.61M in transactions. Which NewAmsterdam Pharma major shareholders have been selling company stock? The following institutional investors have sold NewAmsterdam Pharma stock in the last 24 months: JPMorgan Chase & Co. ($10.90K), and Citadel Advisors LLC ($10.35K). How much institutional selling is happening at NewAmsterdam Pharma? Institutional investors have sold a total of 21,255 shares in the last 24 months. This volume of shares sold represents approximately $0.25M in transactions. Related Companies: Janux Therapeutics Major Shareholders Amphastar Pharmaceuticals Major Shareholders Structure Therapeutics Major Shareholders Maravai LifeSciences Major Shareholders Avidity Biosciences Major Shareholders PTC Therapeutics Major Shareholders Galapagos Major Shareholders Vera Therapeutics Major Shareholders Dyne Therapeutics Major Shareholders Catalyst Pharmaceuticals Major Shareholders This page (NASDAQ:NAMS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubThe 3rd Revolution in WarfareWeiss RatingsWARNING - this content may be disturbingParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.